e-learning
resources
Milan 2017
Sunday, 10.09.2017
Classifying COPD with multidimensional scores and biomarkers
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
GOLD 2011 versus GOLD 2017 – What does change?
A. Caldas Marçôa (Matosinhos, Portugal)
Source:
International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers
Session:
Classifying COPD with multidimensional scores and biomarkers
Session type:
Thematic Poster
Number:
1097
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Caldas Marçôa (Matosinhos, Portugal). GOLD 2011 versus GOLD 2017 – What does change?. 1097
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
The same COPD patients, different GOLD criteria – what are the consequences of changing GOLD 2007-2011-2017 recommendations?
Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS)
Year: 2018
Survival in three years of COPD patients according to GOLD 2003 and GOLD 2014
Source: International Congress 2015 – Latest insights into the management of chronic respiratory diseases
Year: 2015
Changes in GOLD Classifications: 2011 versus 2017. Do exacerbations have any role in mortality?
Source: International Congress 2017 – COPD management: new findings from large studies
Year: 2017
GOLD 2017 versus GOLD 2011 - comparison of the risk of exacerbations and mortality in COPD patients
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018
New GOLD 2011 guidelines: Is there an improvement?
Source: Annual Congress 2012 - Quality of life and clinical parametres in monitoring airway diseases
Year: 2012
The impact of the three GOLD severity classifications of COPD (2001, 2011 and 2017) in the same population of patients.
Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers
Year: 2017
Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?
Source: Eur Respir J 2014; 43: 1201-1203
Year: 2014
COPD severity using GOLD 2017 in real life: The French Palomb Cohort
Source: International Congress 2017 – COPD: from screening to risk factors of lung cancer
Year: 2017
Mortality and exacerbation prediction by GOLD groups ABCD 2011 vs. 2017: analysis of the COPDGene cohort
Source: International Congress 2017 – COPD management: new findings from large studies
Year: 2017
Differences in the recommended initial therapy of COPD according to GOLD guidelines 2006 and 2011
Source: Annual Congress 2012 - GOLD guidelines 2011: new assessment of COPD
Year: 2012
The distribution of COPD in UK general practice using the 2017 GOLD classification
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017
COPD GOLD stage 1: Is it really a disease?
Source: Annual Congress 2011 - COPD mechanisms
Year: 2011
2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the ’real-life’ DACCORD study
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016
The 2006 and 2011 GOLD classifications and five-years mortality in COPD
Source: Annual Congress 2013 –Monitoring symptoms and quality of life
Year: 2013
Usefulness of COPD assessment test (CATÔ) for the management of COPD according to GOLD 2011
Source: Annual Congress 2012 - COPD: epidemiology and varia
Year: 2012
Efficacy of revefenacin based on GOLD 2017 categories: reanalysis of phase 3 data in patients with COPD
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Implementation of the GOLD 2017 disease classification in a real-life COPD cohort
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018
An old disease from a new perspective – GOLD 2011 recommendations for COPD
Source: Annual Congress 2012 - COPD: epidemiology and varia
Year: 2012
Late Breaking Abstract - Adherence to GOLD recommendations in Italian COPD patients stratified by GOLD groups A–D: The MISTRAL study
Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care
Year: 2017
Validation of the GOLD 2017 classification in a Chinese COPD cohort
Source: International Congress 2017 – What is new in COPD diagnosis and classification?
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept